Merck & Company (MRK) 53.03 $MRK
Exelixis, Inc. Earnings: Riding the Meteor
Brian Orelli, The Motley Fool - Motley Fool - 30 mins ago
Exelixis reported earnings on Tuesday, and as usual, the pipeline was much more important for the biotech than its revenue and profit. Exelixis results: The raw numbers Metric Q3 2015 Actuals Q3 2014 Actuals Growth (YOY)...
MRK: 53.03 (unch), BMY: 64.15 (+0.43), EXEL: 5.40 (-0.01)
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting(R)
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-naive patients with compensated liver cirrhosis who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28/31) and 98 percent (135/138), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74/81) and 89 percent (48/54), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 16 or 18 weeks achieved virologic cure rates of 100 percent (49/49) and 94 percent (46/49), respectively. These data will be presented during an oral presentation at The Liver Meeting(R) (Abstract #42).
MRK: 53.03 (unch)
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company's Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Ninety-five percent (189/198) of patients treated with elbasvir/grazoprevir for 12 weeks in the pre-specified primary efficacy analysis population achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, considered virologic cure). Adherence to treatment was high, with 97 percent of patients taking at least 95 percent of their study medication over the 12 weeks of therapy. These findings will be featured today at the American Association for the Study of Liver Diseases' President's Press Conference at The Liver Meeting(R) and presented in an oral session on Monday, November 16 (Abstract #40).
MRK: 53.03 (unch)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 52.72 (-1.20), SWKS: 74.83 (-1.01), GILD: 102.57 (-1.66), SUNE: 4.93 (+0.39), FB: 103.95 (-4.07), MRK: 53.03 (unch), STZ: 132.20 (-1.18), ILMN: 165.65 (+10.26), AAPL: 112.34 (-3.38)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), REGN: 548.90 (-3.63)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BXLT: 33.79 (+0.54)
Immune Design Posts Narrower-Than-Expected Loss for Q3
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:35AM CST
Immune Design's (IMDZ) Q3 loss was narrower than expected.
IMDZ: 18.09 (+1.29), MRK: 53.03 (unch), CORT: 4.80 (-0.04), SNY: 42.99 (-0.65)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BMY: 64.15 (+0.43)
Merck Provides Update on REVEAL Outcomes Study
Business Wire - Fri Nov 13, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck remains blinded to the actual results of this analysis and to other REVEAL safety and efficacy data.
MRK: 53.03 (unch)
Bionomics and MSD Hosting Cognition and Alzheimer's Symposium Featuring Australian and US Speakers
PR Newswire - Fri Nov 13, 5:00AM CST
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will co-host a one-day symposium in Adelaide at the Crowne Plaza, Hindmarsh Square on Monday 16 November 2015 on Drug Discovery and Development for Cognition and Alzheimer's Disease featuring Australian and US experts.
MRK: 53.03 (unch), BNO: 14.79 (-0.23)
Merck Animal Health enters into an agreement to acquire Harrisvaccines for undisclosed fee
M2 - Fri Nov 13, 3:43AM CST
Healthcare company Merck Animal Health revealed on Thursday that it has entered into an agreement to acquire Harrisvaccines for an undisclosed value.
MRK: 53.03 (unch)
US Cancer Vaccine Market Outlook 2020
PR Newswire - Thu Nov 12, 6:37PM CST
In the face of an alarmingly rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. Hence, many research institutes and companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease. Amongst the various cancers, those of the respiratory system, digestive system, lymph nodes, prostate and breast are the leading cancers among Americans. The US represents the most promising market for cancer vaccines across the globe, accounting for over 58% share in 2014.
MRK: 53.03 (unch)
Merck Animal Health to Acquire Harrisvaccines
Business Wire - Thu Nov 12, 4:00PM CST
Merck Animal Health (known as MSD Animal Health outside the United States and Canada) and Harrisvaccines, Inc., today announced the companies have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals.
MRK: 53.03 (unch)
Immune Design Starts Mid-Stage Soft Tissue Sarcoma Trial
Zacks Equity Research - Zacks Investment Research - Thu Nov 12, 3:30PM CST
Immune Design (IMDZ) initiated a phase II study on CMB305 for the treatment of soft tissue sarcoma.
IMDZ: 18.09 (+1.29), MRK: 53.03 (unch), CORT: 4.80 (-0.04)
Merck Statement Regarding CUBICIN(R) (daptomycin for injection) Patent Litigation
Business Wire - Thu Nov 12, 10:49AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision validated the patent for CUBICIN(R) (daptomycin for injection) that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020.
MRK: 53.03 (unch)
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 with AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche & Pfizer Dominating
M2 - Thu Nov 12, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4z56z7/global_nonsmall) has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019. The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report includes a discussion of the key vendors operating in this market. The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period. According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients. Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market. Key vendors - AstraZeneca - Celgene - Eli Lilly - F. Hoffmann-La Roche - Pfizer Other prominent vendors - Abbvie - Aetna - Agennix - Amgen - BetaPharma - Bionumerik Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - CBT Pharma - Celldex Therapeutics - Dainippon Pharma - Eisai Pharmaceuticals - GlaxoSmithKline - Helsinn - IMClone Systems - IsisPharma - Kadmon - Kyowa Hakko Kirin - MabVax Therapeutics - Merck - Novartis - OncoGenex - OSI Pharmaceuticals - Peregrine - Pierre Fabre - Qiagen - Sanofi - Synta Pharmaceuticals - Teva Pharmaceuticals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Product profiles Part 05: Introduction Part 06: Disease overview Part 07: Pipeline portfolio Part 08: Market landscape Part 09: Market segmentation by molecule type Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis Part 19: Appendix For more information visit http://www.researchandmarkets.com/research/4z...l_nonsmall
SNTA: 0.43 (-0.01), MRK: 53.03 (unch), CLDX: 14.23 (+0.22), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), GSK: 39.87 (-0.18), BMY: 64.15 (+0.43), NVS: 86.28 (-0.58), CELGZ: 1.17 (-0.03)
4 Observations You May Have Overlooked in Celgene's Q3 Earnings Report
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 12, 5:58AM CST
Image source: U.S. Food and Drug Administration. The wait is over. Last Thursday, before the opening bell, biotech blue-chip stock Celgene reported its third-quarter earnings results. Expectations were high for the fast-growing drugmaker, but...
MRK: 53.03 (unch), AMGN: 151.55 (+0.57), BMY: 64.15 (+0.43), CELG: 107.49 (-1.53)
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
M2 - Thu Nov 12, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/j6j75w/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line" report to their offering. Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Scope: - The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR of 8.5%. - How will immunotherapies such as Keytruda affect growth? - What effect will patent expirations of Tarceva and Alimta have on market value? - The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted therapies in contrast to the market. - What are the common targets and mechanisms of action of pipeline therapies? - Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients? - What implications will the increased focus on targeted therapies have on the future of NSCLC treatment? - Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period. - How have promising late-stage therapies performed in clinical trials? - How would the approval of Rociletinib affect the competitive landscape? - What is the individual commercial forecast for each therapy? - The market forecasts indicate that the US contributes the most to global market value due to a large treatment population and the high price of premium therapies. - How will ACoT and market size vary between the eight major markets? - How could a change in risk factors such as population age or smoking habits influence the market? - Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion. - How do deal frequency and value compare between target families and molecule types? - What were the terms and conditions of key licensing deals? Companies Mentioned - AbbVie - AstraZeneca - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Clovis Oncology - Daiichi Sankyo - Eli Lilly - Merck - Oncogenex Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Roche - Transgene For more information visit http://www.researchandmarkets.com/research/j6...small_cell
CLVS: 99.43 (+0.02), MRK: 53.03 (unch), LLY: 79.55 (-0.31), BMY: 64.15 (+0.43), CELGZ: 1.17 (-0.03)
Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
M2 - Thu Nov 12, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/k3vf87/hepatitis_b) has announced the addition of the "Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth" report to their offering. Globally, the hepatitis B therapeutics market is served moderately well by the available products, of which Baraclude and Viread are the most frequently prescribed. However, both have received black-box warnings from the US Food and Drug Administration (FDA), meaning that the market has a high level of unmet need. Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature. Scope: - The current hepatitis B market contains mainly nucleoside analog reverse transcriptase inhibitors, nucleotide analogs, and interferons. - Will these drugs continue to dominate hepatitis B treatment? - With 81 active pipeline molecules, most of the investigational drug candidates are small molecules and vaccines, comprising 64% of the pipeline. - What are the most prominent small molecules and vaccines in the pipeline? - Do the pipeline molecules offer advantages over commercially proven mechanisms? - Analysis of clinical trials since 2006 has identified a high rate of attrition in hepatitis B products. - How do failure rates vary by product stage of development, molecule type, and mechanism of action? - How do other factors such as average trial duration and trial size influence the costs and risks associated with product development? - Over the 2014-2021 forecast period, the hepatitis B market in the eight major markets is expected to increase in value at a CAGR of 2.3% from $2.9 billion to $3.5 billion. - Which markets make the most significant contribution to the current market size? - What are the epidemiology trends in these markets? - Which factors will influence growth rates in the different major markets? - Despite generic sales erosion resulting from patent expirations, the uptake of premium therapies tenofovir and entecavir will contribute to significant market growth over the forecast period. - Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs? - Which patent expirations will have the most significant impact on the market? Companies Mentioned - Chiva - Dynavax - Ligand - Merck - NeuroVive For more information visit http://www.researchandmarkets.com/research/k3...epatitis_b
MRK: 53.03 (unch)
Merck Falls 1.30% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 11, 4:34PM CST
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $53.68 to a high of $55.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $53.74 on volume of 8.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 53.03 (unch)
Exelixis, Inc. Earnings: Riding the Meteor
Brian Orelli, The Motley Fool - Motley Fool - 30 mins ago
Exelixis reported earnings on Tuesday, and as usual, the pipeline was much more important for the biotech than its revenue and profit. Exelixis results: The raw numbers Metric Q3 2015 Actuals Q3 2014 Actuals Growth (YOY)...
MRK: 53.03 (unch), BMY: 64.15 (+0.43), EXEL: 5.40 (-0.01)
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting(R)
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-naive patients with compensated liver cirrhosis who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28/31) and 98 percent (135/138), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74/81) and 89 percent (48/54), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 16 or 18 weeks achieved virologic cure rates of 100 percent (49/49) and 94 percent (46/49), respectively. These data will be presented during an oral presentation at The Liver Meeting(R) (Abstract #42).
MRK: 53.03 (unch)
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company's Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Ninety-five percent (189/198) of patients treated with elbasvir/grazoprevir for 12 weeks in the pre-specified primary efficacy analysis population achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, considered virologic cure). Adherence to treatment was high, with 97 percent of patients taking at least 95 percent of their study medication over the 12 weeks of therapy. These findings will be featured today at the American Association for the Study of Liver Diseases' President's Press Conference at The Liver Meeting(R) and presented in an oral session on Monday, November 16 (Abstract #40).
MRK: 53.03 (unch)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 52.72 (-1.20), SWKS: 74.83 (-1.01), GILD: 102.57 (-1.66), SUNE: 4.93 (+0.39), FB: 103.95 (-4.07), MRK: 53.03 (unch), STZ: 132.20 (-1.18), ILMN: 165.65 (+10.26), AAPL: 112.34 (-3.38)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.27 (-0.12), MRK: 53.03 (unch), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), REGN: 548.90 (-3.63)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BXLT: 33.79 (+0.54)
Immune Design Posts Narrower-Than-Expected Loss for Q3
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:35AM CST
Immune Design's (IMDZ) Q3 loss was narrower than expected.
IMDZ: 18.09 (+1.29), MRK: 53.03 (unch), CORT: 4.80 (-0.04), SNY: 42.99 (-0.65)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 102.57 (-1.66), MRK: 53.03 (unch), ABBV: 59.86 (-0.37), BMY: 64.15 (+0.43)
Merck Provides Update on REVEAL Outcomes Study
Business Wire - Fri Nov 13, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck remains blinded to the actual results of this analysis and to other REVEAL safety and efficacy data.
MRK: 53.03 (unch)
Bionomics and MSD Hosting Cognition and Alzheimer's Symposium Featuring Australian and US Speakers
PR Newswire - Fri Nov 13, 5:00AM CST
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will co-host a one-day symposium in Adelaide at the Crowne Plaza, Hindmarsh Square on Monday 16 November 2015 on Drug Discovery and Development for Cognition and Alzheimer's Disease featuring Australian and US experts.
MRK: 53.03 (unch), BNO: 14.79 (-0.23)
Merck Animal Health enters into an agreement to acquire Harrisvaccines for undisclosed fee
M2 - Fri Nov 13, 3:43AM CST
Healthcare company Merck Animal Health revealed on Thursday that it has entered into an agreement to acquire Harrisvaccines for an undisclosed value.
MRK: 53.03 (unch)
US Cancer Vaccine Market Outlook 2020
PR Newswire - Thu Nov 12, 6:37PM CST
In the face of an alarmingly rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. Hence, many research institutes and companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease. Amongst the various cancers, those of the respiratory system, digestive system, lymph nodes, prostate and breast are the leading cancers among Americans. The US represents the most promising market for cancer vaccines across the globe, accounting for over 58% share in 2014.
MRK: 53.03 (unch)
Merck Animal Health to Acquire Harrisvaccines
Business Wire - Thu Nov 12, 4:00PM CST
Merck Animal Health (known as MSD Animal Health outside the United States and Canada) and Harrisvaccines, Inc., today announced the companies have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals.
MRK: 53.03 (unch)
Immune Design Starts Mid-Stage Soft Tissue Sarcoma Trial
Zacks Equity Research - Zacks Investment Research - Thu Nov 12, 3:30PM CST
Immune Design (IMDZ) initiated a phase II study on CMB305 for the treatment of soft tissue sarcoma.
IMDZ: 18.09 (+1.29), MRK: 53.03 (unch), CORT: 4.80 (-0.04)
Merck Statement Regarding CUBICIN(R) (daptomycin for injection) Patent Litigation
Business Wire - Thu Nov 12, 10:49AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit. The decision validated the patent for CUBICIN(R) (daptomycin for injection) that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020.
MRK: 53.03 (unch)
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 with AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche & Pfizer Dominating
M2 - Thu Nov 12, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4z56z7/global_nonsmall) has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering. The global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019. The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report includes a discussion of the key vendors operating in this market. The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period. According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients. Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market. Key vendors - AstraZeneca - Celgene - Eli Lilly - F. Hoffmann-La Roche - Pfizer Other prominent vendors - Abbvie - Aetna - Agennix - Amgen - BetaPharma - Bionumerik Pharmaceuticals - Boehringer Ingelheim - Bristol-Myers Squibb - CBT Pharma - Celldex Therapeutics - Dainippon Pharma - Eisai Pharmaceuticals - GlaxoSmithKline - Helsinn - IMClone Systems - IsisPharma - Kadmon - Kyowa Hakko Kirin - MabVax Therapeutics - Merck - Novartis - OncoGenex - OSI Pharmaceuticals - Peregrine - Pierre Fabre - Qiagen - Sanofi - Synta Pharmaceuticals - Teva Pharmaceuticals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Product profiles Part 05: Introduction Part 06: Disease overview Part 07: Pipeline portfolio Part 08: Market landscape Part 09: Market segmentation by molecule type Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis Part 19: Appendix For more information visit http://www.researchandmarkets.com/research/4z...l_nonsmall
SNTA: 0.43 (-0.01), MRK: 53.03 (unch), CLDX: 14.23 (+0.22), AMGN: 151.55 (+0.57), LLY: 79.55 (-0.31), GSK: 39.87 (-0.18), BMY: 64.15 (+0.43), NVS: 86.28 (-0.58), CELGZ: 1.17 (-0.03)
4 Observations You May Have Overlooked in Celgene's Q3 Earnings Report
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 12, 5:58AM CST
Image source: U.S. Food and Drug Administration. The wait is over. Last Thursday, before the opening bell, biotech blue-chip stock Celgene reported its third-quarter earnings results. Expectations were high for the fast-growing drugmaker, but...
MRK: 53.03 (unch), AMGN: 151.55 (+0.57), BMY: 64.15 (+0.43), CELG: 107.49 (-1.53)
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
M2 - Thu Nov 12, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/j6j75w/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line" report to their offering. Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Scope: - The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR of 8.5%. - How will immunotherapies such as Keytruda affect growth? - What effect will patent expirations of Tarceva and Alimta have on market value? - The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted therapies in contrast to the market. - What are the common targets and mechanisms of action of pipeline therapies? - Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients? - What implications will the increased focus on targeted therapies have on the future of NSCLC treatment? - Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period. - How have promising late-stage therapies performed in clinical trials? - How would the approval of Rociletinib affect the competitive landscape? - What is the individual commercial forecast for each therapy? - The market forecasts indicate that the US contributes the most to global market value due to a large treatment population and the high price of premium therapies. - How will ACoT and market size vary between the eight major markets? - How could a change in risk factors such as population age or smoking habits influence the market? - Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion. - How do deal frequency and value compare between target families and molecule types? - What were the terms and conditions of key licensing deals? Companies Mentioned - AbbVie - AstraZeneca - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene Corporation - Clovis Oncology - Daiichi Sankyo - Eli Lilly - Merck - Oncogenex Pharmaceuticals - Peregrine Pharmaceuticals - Pfizer - Roche - Transgene For more information visit http://www.researchandmarkets.com/research/j6...small_cell
CLVS: 99.43 (+0.02), MRK: 53.03 (unch), LLY: 79.55 (-0.31), BMY: 64.15 (+0.43), CELGZ: 1.17 (-0.03)
Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth
M2 - Thu Nov 12, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/k3vf87/hepatitis_b) has announced the addition of the "Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth" report to their offering. Globally, the hepatitis B therapeutics market is served moderately well by the available products, of which Baraclude and Viread are the most frequently prescribed. However, both have received black-box warnings from the US Food and Drug Administration (FDA), meaning that the market has a high level of unmet need. Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature. Scope: - The current hepatitis B market contains mainly nucleoside analog reverse transcriptase inhibitors, nucleotide analogs, and interferons. - Will these drugs continue to dominate hepatitis B treatment? - With 81 active pipeline molecules, most of the investigational drug candidates are small molecules and vaccines, comprising 64% of the pipeline. - What are the most prominent small molecules and vaccines in the pipeline? - Do the pipeline molecules offer advantages over commercially proven mechanisms? - Analysis of clinical trials since 2006 has identified a high rate of attrition in hepatitis B products. - How do failure rates vary by product stage of development, molecule type, and mechanism of action? - How do other factors such as average trial duration and trial size influence the costs and risks associated with product development? - Over the 2014-2021 forecast period, the hepatitis B market in the eight major markets is expected to increase in value at a CAGR of 2.3% from $2.9 billion to $3.5 billion. - Which markets make the most significant contribution to the current market size? - What are the epidemiology trends in these markets? - Which factors will influence growth rates in the different major markets? - Despite generic sales erosion resulting from patent expirations, the uptake of premium therapies tenofovir and entecavir will contribute to significant market growth over the forecast period. - Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs? - Which patent expirations will have the most significant impact on the market? Companies Mentioned - Chiva - Dynavax - Ligand - Merck - NeuroVive For more information visit http://www.researchandmarkets.com/research/k3...epatitis_b
MRK: 53.03 (unch)
Merck Falls 1.30% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 11, 4:34PM CST
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $53.68 to a high of $55.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $53.74 on volume of 8.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 53.03 (unch)
